Table 3A
  S1PR2 Asn10Lys  
  Asn10Asn Asn10Lys Lys10Lys Pearson Chi²
hypertension 58.90% (1949) 57.02% (65) 100% (1) 0.6503
no hypertension 41.10% (1360) 42.98% (49) 0% (0)
acute coronary syndrome 31.07% (1028) 31.58% (36) 100% (1) 0.3281
no acute coronary syndrome 68.93% (2281) 68.42% (78) 0% (0)
left ventricular hypertrophy 8.25% (273) 5.26% (6) 0% (0) 0.4960
no left ventricular hypertrophy 91.75% (3036) 94.74% (108) 100% (1)
coronary artery disease 77.33% (2559) 80.70% (92) 100% (1) 0.6045
no coronary artery disease 22.67% (750) 19.30% (22) 0% (0)
peripheral vascular disease 9.73% (322) 8.77% (10) 0% (0) 0.8944
no peripheral vascular disease 90.27% (2987) 91.23% (104) 100% (1)
angina pectoris 53.78% (1715) 53.15% (59) 0% (0) 0.5546
no angina pectoris 46.22% (1474) 46.85% (52) 100% (1)
myocardial infarction 39.62% (1311) 47.37% (54) 100% (1) 0.1184
no myocardial infarction 60.38% (1998) 53.63% (60) 0% (0)
unrecognized myocardial infarction 8.77% (237) 5.49% (5) 0% (0) 0.5253
no unrecognized myocardial infarction 91.23% (2466) 94.51% (86) 100% (1)
premature myocardial infarction 17.53% (580) 18.42% (21) 100% (1) 0.8721
no premature myocardial infarction 82.47% (2729) 81.58% (93) 0% (0)
venous thrombosis / pulmonary embolism 6.30% (208) 4.39% (5) 100% (1) 0.6846
no venous thrombosis / pulmonary embolism 93.70% (3093) 95.61% (109) 0% (0)
stroke/TIA/PRIND 8.04% (266) 7.89% (9) 100% (1) 0.9558
no stroke/TIA/PRIND 91.96% (3043) 92.11% (105) 0% (0)
arrhythmia 14.84% (485) 15.93% (18) 0% (0) 0.0546
no arrhythmia 85.16% (2783) 84.07% (95) 100% (1)
diabetes 31.58% (1045) 35.96% (41) 0% (0) 0.2093
no diabetes 68.42% (2264) 64.04% (73) 100% (1)
 
Table 3B
  S1PR2 Val286Ala  
  Val286Val Val286Ala Pearson Chi²
hypertension 58.82% (1970) 61.97% (44) 0.5937
no hypertension 41.18% (1379) 38.03% (27)
acute coronary syndrome 31.17% (1044) 30.99% (22) 0.9731
no acute coronary syndrome 68.83% (2305) 69.01% (49)
left ventricular hypertrophy 8.09% (271) 11.27% (8) 0.3334
no left ventricular hypertrophy 91.91% (3078) 88.73% (63)
coronary artery disease 77.61% (2599) 74.65% (53) 0.5546
no coronary artery disease 22.39% (759) 25.35% (18)
peripheral vascular disease 9.73% (326) 9.86% (7) 0.9720
no peripheral vascular disease 90.27% (3023) 90.14% (64)
angina pectoris 53.72% (1735) 59.70% (40) 0.3306
no angina pectoris 46.28% (1495) 40.30% (27)
myocardial infarction 40.13% (1344) 30.99% (22) 0.1195
no myocardial infarction 59.87% (2005) 69.01% (49)
unrecognized myocardial infarction 8.62% (236) 10.71% (6) 0.5818
no unrecognized myocardial infarction 91.38% (2501) 89.29% (50)
premature myocardial infarction 17.62% (590) 11.27% (8) 0.1634
no premature myocardial infarction 82.38% (2759) 88.73% (63)
venous thrombosis / pulmonary embolism 6.14% (205) 11.27% (8) 0.0770
no venous thrombosis / pulmonary embolism 93.86% (3136) 88.73% (63)
stroke/TIA/PRIND 8.06% (270) 5.63% (4) 0.4558
no stroke/TIA/PRIND 91.94% (3079) 94.37% (67)
arrhythmia 15.03% (497) 11.43% (8) 0.4033
no arrhythmia 84.97% (2810) 88.57% (62)
diabetes 31.50% (1055) 49.30% (35) 0.0015
*0.0008
no diabetes 68.50% (2294) 50.70% (36)
* After logistic regression for age, body mass index, gender and smoker status. Risk ratio for incidence of diabetes 1.084 (95% CI 1.035-1.140).
Table 3: Association analyses between the S1PR2 polymorphisms Asn10Lys (Table 3A) and Val286Ala (Table 3B) and clinical endpoints in patients of the LURIC study. Figures indicate the percentage (%) and number of patients with the given clinical endpoint in the group of individuals with the same S1PR2 genotype. The clinical endpoints listed in the tables are based on questionnaire data, the patient record or have been diagnosed during hospitalization/inclusion phase in the LURIC study. Definitions for disease diagnosis are listed in Patients and Methods under Study Population.